{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T20:10:57Z","timestamp":1775333457128,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.14310\/horm.2002.1501","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T13:03:02Z","timestamp":1402923782000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Graves\u2019 disease after treatment with Alemtuzumab for multiple sclerosis"],"prefix":"10.1007","volume":"14","author":[{"given":"Elena","family":"Tsourdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Blankenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,1]]},"reference":[{"key":"14010148_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SA Thompson","year":"2010","unstructured":"Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ, 2010 B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30: 99\u2013105.","journal-title":"J Clin Immunol"},{"key":"14010148_CR2","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","volume":"100","author":"AG Buggins","year":"2002","unstructured":"Buggins AG, Mufti GJ, Salisbury J, et al, 2002 Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 100: 1715\u20131720.","journal-title":"Blood"},{"key":"14010148_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","volume":"253","author":"AJ Coles","year":"2006","unstructured":"Coles AJ, Cox A, Le Page E, et al, 2006 The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98\u2013108.","journal-title":"J Neurol"},{"key":"14010148_CR4","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"Coles AJ, Compston DA, Selmaj KW, et al, CAMMS 223 Trial Investigators, 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786\u20131801.","journal-title":"N Engl J Med"},{"key":"14010148_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al, CARE-MS I investigators, 2012 Alemtuzumab versus interferon beta la as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819\u20131828.","journal-title":"Lancet"},{"key":"14010148_CR6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al, CARE-MS II investigators, 2012 Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet 380: 1829\u20131839.","journal-title":"Lancet"},{"key":"14010148_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00415-008-0696-y","volume":"255","author":"CL Hirst","year":"2008","unstructured":"Hirst CL, Pace A, Pickersgill TP, et al, 2008 Campath 1-H treatment in patients with aggressive remitting multiple sclerosis. J Neurol 255: 231\u2013238.","journal-title":"J Neurol"},{"key":"14010148_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2011.04.006","volume":"142","author":"L Klotz","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H, 2012 Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142: 25\u201330.","journal-title":"Clin Immunol"},{"key":"14010148_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S, et al, 1999 Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691\u20131695.","journal-title":"Lancet"},{"key":"14010148_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.bmt.1701437","volume":"22","author":"Y Sherer","year":"1998","unstructured":"Sherer Y, Shoenfeld Y, 1998 Autoimmune diseases and autoimmune post-bone marrow transplantation. Bone Marrow Transplant 22: 873\u2013881.","journal-title":"Bone Marrow Transplant"},{"key":"14010148_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4158\/EP.15.1.53","volume":"15","author":"AP Weetman","year":"2009","unstructured":"Weetman AP, 2009 \u201cIoning out thyroid autoimmunity\u201d. Endocr Pract 15: 53\u201355.","journal-title":"Endocr Pract"},{"key":"14010148_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjmed.2012.05.012","volume":"125","author":"JA Sipos","year":"2012","unstructured":"Sipos JA, Kahaly GJ, 2012 Imaging of thyreotoxicosis. Am J Med 125: 1\u20132.","journal-title":"Am J Med"},{"key":"14010148_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje.1.02230","volume":"155","author":"WM Wiersinga","year":"2006","unstructured":"Wiersinga WM, Perros P, Kahaly GJ, et al, 2006 Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387\u2013389.","journal-title":"Eur J Endocrinol"},{"key":"14010148_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1749-6632.2002.tb04215.x","volume":"966","author":"L Castagnetta","year":"2002","unstructured":"Castagnetta L, Granata OM, Traina A, et al, 2002 A role for sex steroids in autoimmune diseases: a working hypothesis and supporting data. Ann NY Acad Sci 966: 193\u2013203.","journal-title":"Ann NY Acad Sci"},{"key":"14010148_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1096\/fj.01-0998hyp","volume":"16","author":"V Estienne","year":"2002","unstructured":"Estienne V, Duthoit C, Reichert M, et al, 2002 Androgen-dependent expression of FCgammaRIIB2 by thyrocytes from patients with autoimmune Graves\u2019 disease: a possible molecular clue for sex dependence of autoimmune disease. FASEB J 16: 1087\u20131092.","journal-title":"FASEB J"},{"key":"14010148_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","volume":"173","author":"D Fairweather","year":"2008","unstructured":"Fairweather D, Frisancho-Kiss S, Rose NR, 2008 Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173: 600\u2013609.","journal-title":"Am J Pathol"},{"key":"14010148_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","volume":"5","author":"JP Pearl","year":"2005","unstructured":"Pearl JP, Parris J, Hale DA, et al, 2005 Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5: 465\u2013474.","journal-title":"Am J Transplant"},{"key":"14010148_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS, 2010 Graves\u2019 ophthalmopathy. N Engl J Med 362: 726\u2013738.","journal-title":"N Engl J Med"},{"issue":"Suppl2","key":"14010148_CR19","first-page":"198","volume":"7","author":"A Eckstein","year":"2010","unstructured":"Eckstein A, Esser J, Mann K, Schott M, 2010 Clinical value of TSH receptor antibodies measurement in patients with Graves\u2019 orbitopathy. Pediatr Endocrinol Rev 7: Suppl 2: 198\u2013203.","journal-title":"Pediatr Endocrinol Rev"},{"key":"14010148_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2265.2009.03682.x","volume":"72","author":"P Iglesias","year":"2010","unstructured":"Iglesias P, Devora O, Garcia J, et al, 2010 Severe hyperthyroidism: aetiology, clinical features and treatment outcome. Clin Endocrinol 72: 551\u2013557.","journal-title":"Clin Endocrinol"},{"key":"14010148_CR21","first-page":"1","volume":"11","author":"AA Aranha","year":"2013","unstructured":"Aranha AA, Amer S, Reda ES, et al, 2013 Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review. Endocr Pract 11: 1\u201325.","journal-title":"Endocr Pract"},{"key":"14010148_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.2012.0514","volume":"23","author":"AB Glick","year":"2013","unstructured":"Glick AB, Wodzinski A, Fu P, et al, 2013 Impairment of regulatory T cell function in autoimmune thyroid disease. Thyroid 23: 871\u2013878.","journal-title":"Thyroid"},{"key":"14010148_CR23","first-page":"2052","volume":"119","author":"JL Jones","year":"2009","unstructured":"Jones JL, Phuah CL, Cox AL, et al, 2009 IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119: 2052\u20132061.","journal-title":"J Clin Invest"},{"key":"14010148_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","volume":"128","author":"Y Hu","year":"2009","unstructured":"Hu Y, Turner MJ, Shields J, et al, 2009 Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse. Immunology 128: 260\u2013270.","journal-title":"Immunology"},{"key":"14010148_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1507\/endocrj.K07E-006","volume":"55","author":"M Watanabe","year":"2008","unstructured":"Watanabe M, Nakamura Y, Matsuzuka F, et al, 2008 Decrease of intrathyroidal CD161+Valpha24+Vbeta11+NKT cells in Graves\u2019 disease. Endocr J 55: 199\u2013203.","journal-title":"Endocr J"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1501\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:37:56Z","timestamp":1739115476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["14010148"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1501","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"31 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}